Piper Sandler raised the firm’s price target on Abivax (ABVX) to $70 from $42 and keeps an Overweight rating on the shares following disclosure of positive topline induction data from the Phase 3 ABTECT program evaluating obefazimod in ulcerative colitis. The firm awaits UC maintenance data in Q2 2026 and filing thereafter, but bottom line, believes the update validates obefazimod’s highly-differentiated profile and warrants an increase to its revenue estimates and price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
- Abivax price target raised to $95 from $33 at Citizens JMP
- Abivax SA – American Depositary Shares trading resumes
- Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment
- Abivax says obefazimod met primary endpoint in ABTECT-1, ABTECT-2 trials